Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
SYN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.95%171.301.3%$495.18m
BIIBBiogen Inc.
0.91%235.041.3%$480.36m
CELGCelgene Corporation
0.11%96.361.3%$457.23m
GILDGilead Sciences, Inc.
-0.03%66.500.9%$434.72m
ILMNIllumina, Inc.
2.08%312.833.5%$317.70m
REGNRegeneron Pharmaceuticals, Inc.
3.27%320.092.6%$298.61m
AAgilent Technologies, Inc.
-0.50%67.981.6%$207.68m
VRTXVertex Pharmaceuticals Incorporated
1.92%172.371.9%$181.17m
EXASExact Sciences Corporation
-2.10%94.9125.3%$163.66m
ALXNAlexion Pharmaceuticals, Inc.
-0.97%127.552.0%$149.64m
BMRNBioMarin Pharmaceutical Inc.
0.25%87.694.3%$118.55m
SRPTSarepta Therapeutics, Inc.
0.36%121.6214.7%$112.14m
INCYIncyte Corporation
0.43%79.022.5%$105.72m
IONSIonis Pharmaceuticals, Inc.
-0.98%68.568.2%$98.74m
ALNYAlnylam Pharmaceuticals, Inc
-0.09%67.819.2%$94.94m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.